NHS England launches public consultation on PrEP commissioning proposals

11 August 2016

NHS England has launched a 45-day public consultation on a proposed clinical commissioning policy for Pre-Exposure Prophylaxis (PrEP) for HIV.

NHS England proposes to routinely commission PrEP for the treatment of adults at high risk of HIV acquisition, including men who have sex with men (MSM), trans men and women and some heterosexuals who are considered high risk.

The consultation follows a ruling by the High Court earlier this month which overturned a decision by NHS England to remove PrEP from its commissioning process on the grounds that it lacked the legal power to fund the treatment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK